Statin Utilization among Patients with Acute Coronary Syndrome: Systematic Review

Pramitha Esha Nirmala Dewi; Montarat  Thavorncharoensap

doi:10.3889/oamjms.2021.5807

Authors

Pramitha Esha Nirmala Dewi Department of Pharmacy Profession https://orcid.org/0000-0001-5384-3595
Montarat Thavorncharoensap Social

DOI:

https://doi.org/10.3889/oamjms.2021.5807

Keywords:

Acute coronary syndrome, Prescribing pattern, Statin utilization

Abstract

BACKGROUND: The early use of statin with intensive regimen has been recommended by the recent guidelines as the prevention of acute coronary syndrome (ACS) related events among the high-risk patients. Meanwhile, the inconsistent statin utilization for targeted patient in current practice is still an issue.

AIM: This study aims to review the utilization rate of statin among patients with ACS.

METHODS: A systematic search of relevant studies published between inceptions to June 2020 was conducted in PubMed. Patients and intervention domains were used to build up the searching formula. A study was eligible for inclusion if it was an original study of patients with ACS and it examined the utilization of statin. The risk of bias was assessed using Axis and NOS checklist.

RESULTS: Among the 49 eligible studies, 38 were cohort studies while the others were cross-sectional studies. The utilization rate of statin at hospital admission ranged from 16% to 61% while 25% to 75% during the hospitalization. Of the total studies, 35 studies reported the statin rate at discharge ranging from 58% to 99%. Almost all studies revealed the reduction of statin utilization rate along the follow-up period. The number of statins prescribed was found to be lower among female and elderly patients.

CONCLUSION: Despite the established benefits of statin among patients with ACS, our study revealed that statin was underutilized for secondary prevention after ACS. To improve patients’ clinical outcomes with ACS, efforts should be made to increase optimal treatment and compliance with a statin.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Ritchie MRaH. Burden of Disease; 2017. Available from: https://www.ourworldindata.org/burden-of-disease. [Last accessed on 2020 Aug 11]

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. https://doi.org/10.15829/1560-4071-2020-3826 PMid:31504418 DOI: https://doi.org/10.15829/1560-4071-2020-3826

Ruscica M, Macchi C, Pavanello C, Corsini A, Sahebkar A, Sirtori CR. Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018;50:33-40. https://doi.org/10.1016/j.ejim.2017.12.011 PMid:29310996 DOI: https://doi.org/10.1016/j.ejim.2017.12.011

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. https://doi.org/10.1161/01.cir.0000437738.63853.7a PMid:24239923 DOI: https://doi.org/10.1161/01.cir.0000437738.63853.7a

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-646. https://doi.org/10.1161/cir.0000000000000725 PMid:30879355 DOI: https://doi.org/10.1161/CIR.0000000000000725

Shehab A, Al-Dabbagh B, AlHabib KF, Alsheikh-Ali AA, Almahmeed W, Sulaiman K, et al. Gender disparities in the presentation, management and outcomes of acute coronary syndrome patients: Data from the 2nd Gulf Registry of Acute Coronary Events (Gulf RACE-2). PLoS One. 2013;8(2):e55508. https://doi.org/10.1371/journal.pone.0055508 PMid:23405162 DOI: https://doi.org/10.1371/journal.pone.0055508

Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443-50. https://doi.org/10.1002/clc.22007 PMid:22588943 DOI: https://doi.org/10.1002/clc.22007

Wong CK, Tang EW, Herbison P. Prognostic interactions between statins and in-hospital revascularisation on the outcome of acute coronary syndrome. Heart Lung Circ. 2009;18(4):262-5. https://doi.org/10.1016/j.hlc.2008.12.001 PMid:19167924 DOI: https://doi.org/10.1016/j.hlc.2008.12.001

Selby K, Nanchen D, Auer R, Gencer B, Räber L, Klingenberg R, et al. Low statin use in adults hospitalized with acute coronary syndrome. Prev Med. 2015;77:131-6. https://doi.org/10.1016/j.ypmed.2015.05.012 PMid:26007299 DOI: https://doi.org/10.1016/j.ypmed.2015.05.012

Eisen A, Cannon CP, Braunwald E, Steen DL, Zhou J, Goodrich EL, et al. Predictors of nonuse of a high-potency statin after an acute coronary syndrome: Insights from the stabilization of plaques using darapladib-thrombolysis in myocardial infarction 52 (SOLID-TIMI 52) trial. J Am Heart Assoc. 2017;6(1):e004332. https://doi.org/10.1161/jaha.116.004332 PMid:28077384 DOI: https://doi.org/10.1161/JAHA.116.004332

Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):e011458. https://doi.org/10.1136/bmjopen-2016-011458 PMid:27932337 DOI: https://doi.org/10.1136/bmjopen-2016-011458

Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. UK: University of Liverpool; 2000.

Vermeer NS, Bajorek BV. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. J Clin Pharm Ther. 2008;33(6):591-601. https://doi.org/10.1111/j.1365-2710.2008.00950.x PMid:19138236 DOI: https://doi.org/10.1111/j.1365-2710.2008.00950.x

Abdallah M, Karrowni W, Shamseddeen W, Itani S, Kobeissi L, Ghazzal Z, et al. Acute coronary syndromes: Clinical characteristics, management, and outcomes at the American University of Beirut Medical Center, 2002-2005. Clin Cardiol. 2010;33(1):E6-13. https://doi.org/10.1002/clc.20636 PMid:20014175 DOI: https://doi.org/10.1002/clc.20636

Kassab YW, Hassan Y, Aziz NA, Akram H, Ismail O. Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice. J Eval Clin Pract. 2013;19(4):658-63. https://doi.org/10.1111/j.1365-2753.2012.01894.x PMid:22845427 DOI: https://doi.org/10.1111/j.1365-2753.2012.01894.x

Shimony A, Grandi SM, Pilote L, Joseph L, O’Loughlin J, Paradis G, et al. Utilization of evidence-based therapy for acute coronary syndrome in high-income and low/middleincome countries. Am J Cardiol. 2014;113(5):793-7. https://doi.org/10.1016/j.amjcard.2013.11.024 PMid:24440324 DOI: https://doi.org/10.1016/j.amjcard.2013.11.024

Ramanath VS, Armstrong DF, Grzybowski M, Rahnama-Mohagdam S, Tamhane UU, Gordon K, et al. Receipt of cardiac medications upon discharge among men and women with acute coronary syndrome and nonobstructive coronary artery disease. Clin Cardiol. 2010;33(1):36-41. https://doi.org/10.1002/clc.20701 PMid:20063300 DOI: https://doi.org/10.1002/clc.20701

Aliprandi-Costa B, Ranasinghe I, Chow V, Kapila S, Juergens C, Devlin G, et al. Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000-2007. Med J Aust. 2011;195(3):116-21. https://doi.org/10.5694/j.1326-5377.2011.tb03237.x PMid:21806528 DOI: https://doi.org/10.5694/j.1326-5377.2011.tb03237.x

Ranasinghe I, Naoum C, Aliprandi-Costa B, Sindone AP, Steg PG, Elliott J, et al. Management and outcomes following an acute coronary event in patients with chronic heart failure 1999-2007. Eur J Heart Fail. 2012;14(5):464-72. https://doi.org/10.1093/eurjhf/hfs041 PMid:22499543 DOI: https://doi.org/10.1093/eurjhf/hfs041

Gausia K, Katzenellenbogen JM, Sanfilippo FM, Knuiman MW, Thompson PL, Hobbs MS, et al. Evidence-based prescribing of drugs for secondary prevention of acute coronary syndrome in Aboriginal and non-Aboriginal patients admitted to Western Australian hospitals. Intern Med J. 2014;44(4):353-61. https://doi.org/10.1111/imj.12375 PMid:24528930 DOI: https://doi.org/10.1111/imj.12375

Ghadri JR, Sarcon A, Jaguszewski M, Diekmann J, Bataiosu RD, Hellermann J, et al. Gender disparities in acute coronary syndrome: A closing gap in the short-term outcome. J Cardiovasc Med (Hagerstown). 2015;16(5):355-62. https://doi.org/10.2459/jcm.0000000000000248 PMid:25826477 DOI: https://doi.org/10.2459/JCM.0000000000000248

Medagama A, Bandara R, De Silva C, Galgomuwa MP. Management of acute coronary syndromes in a developing country; time for a paradigm shift? An observational study. BMC Cardiovasc Disord. 2015;15:133. https://doi.org/10.1186/s12872-015-0125-y PMid:26497226 DOI: https://doi.org/10.1186/s12872-015-0125-y

Anzai A, Maekawa Y, Kodaira M, Mogi S, Arai T, Kawakami T, et al. Prognostic implications of optimal medical therapy in patients undergoing percutaneous coronary intervention for acute coronary syndrome in octogenarians. Heart Vessels. 2015;30(2):186-92. https://doi.org/10.1007/s00380-014-0474-y PMid:24493327 DOI: https://doi.org/10.1007/s00380-014-0474-y

Boccara F, Miantezila Basilua J, Mary-Krause M, Lang S, Teiger E, Steg PG, et al. Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. Am Heart J. 2017;183:91-101. https://doi.org/10.1016/j.ahj.2016.10.013 PMid:27979047 DOI: https://doi.org/10.1016/j.ahj.2016.10.013

Hoedemaker NP, Damman P, Ottervanger JP, Dambrink JH, Gosselink AT, Kedhi E, et al. Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: A 9-year experience in a real-world setting. Eur Heart J Cardiovasc Pharmacother. 2018;4(2):102-10. https://doi.org/10.1093/ehjcvp/pvy005 PMid:29394340 DOI: https://doi.org/10.1093/ehjcvp/pvy005

Boklage SH, Malangone-Monaco E, Lopez-Gonzalez L, Ding Y, Henriques C, Elassal J. Statin utilization patterns and outcomes for patients with acute coronary syndrome during and following inpatient admissions. Cardiovasc Drugs Ther. 2018;32(3):273-80. https://doi.org/10.1007/s10557-018-6800-3 PMid:29855748 DOI: https://doi.org/10.1007/s10557-018-6800-3

Bi Y, Gao R, Patel A, Su S, Gao W, Hu D, et al. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: Results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J. 2009;157(3):509-16. https://doi.org/10.1016/j.ahj.2008.09.026 PMid:19249422 DOI: https://doi.org/10.1016/j.ahj.2008.09.026

Melloni C, Shah BR, Ou FS, Roe MT, Smith SC Jr., Pollack CV Jr., et al. Lipid-lowering intensification and lowdensity lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry. Am Heart J. 2010;160(6):1121-9. https://doi.org/10.1016/j.ahj.2010.09.008 PMid:21146667 DOI: https://doi.org/10.1016/j.ahj.2010.09.008

ACCESS Investigators. Management of acute coronary syndromes in developing countries: Acute coronary events-a multinational survey of current management strategies. Am Heart J. 2011;162(5):852-9. https://doi.org/10.1016/j.ahj.2011.07.029 PMid:22093201 DOI: https://doi.org/10.1016/j.ahj.2011.07.029

Andrikopoulos G, Tzeis S, Mantas I, Olympios C, Kitsiou A, Kartalis A, et al. Epidemiological characteristics and in-hospital management of acute coronary syndrome patients in Greece: Results from the TARGET study. Hellenic J Cardiol. 2012;53(1):33-40. PMid:22275741

Jin H, Tang C, Wei Q, Chen L, Sun Q, Ma G, et al. Agerelated differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital discharge. BMC Cardiovasc Disord. 2014;14(1):127. https://doi.org/10.1186/1471-2261-14-127 PMid:25252927 DOI: https://doi.org/10.1186/1471-2261-14-127

Kassaian SE, Masoudkabir F, Sezavar H, Mohammadi M, Pourmoghaddas A, Kojuri J, et al. Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: The Iranian Project for Assessment of Coronary Events 2 (IPACE2). BMJ Open. 2015;5(12):e007786. https://doi.org/10.1136/bmjopen-2015-007786 PMid:26671947 DOI: https://doi.org/10.1136/bmjopen-2015-007786

Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez AF, et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010;160(6):1130-6. https://doi.org/10.1016/j.ahj.2010.08.041 PMid:21146668 DOI: https://doi.org/10.1016/j.ahj.2010.08.041

Hao Y, Liu J, Liu J, Yang N, Smith SC, Jr., Huo Y, et al. Sex differences in in-hospital management and outcomes of patients with acute coronary syndrome. Circulation. 2019;139(15):1776-85. PMid:30667281 DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.037655

Amar J, Ferrieres J, Cambou JP, Amelineau E, Danchin N. Persistence of combination of evidence-based medical therapy in patients with acute coronary syndromes. Arch Cardiovasc Dis. 2008;101(5):301-6. https://doi.org/10.1016/j.acvd.2008.04.005 PMid:18656088 DOI: https://doi.org/10.1016/j.acvd.2008.04.005

Wai A, Pulver LK, Oliver K, Thompson A. Current discharge management of acute coronary syndromes: Baseline results from a national quality improvement initiative. Intern Med J. 2012;42(5):e53-9. https://doi.org/10.1111/j.1445-5994.2010.02308.x PMid:20646093 DOI: https://doi.org/10.1111/j.1445-5994.2010.02308.x

Wong CK, Tang EW, Herbison P. The use of different evidencebased medications and 5-year survival after an acute coronary syndrome: An observational study. Int J Cardiol. 2009;132(2):197-202. https://doi.org/10.1016/j.ijcard.2007.11.005 PMid:18191242 DOI: https://doi.org/10.1016/j.ijcard.2007.11.005

Maggioni AP, Rossi E, Cinconze E, De Rosa M. Use and misuse of statins after ACS: Analysis of a prescription database of a community setting of 2,042,968 subjects. Eur J Prev Cardiol. 2014;21(9):1109-16. https://doi.org/10.1177/2047487313485511 PMid:23539716 DOI: https://doi.org/10.1177/2047487313485511

Gunnell AS, Hung J, Knuiman MW, Nedkoff L, Gillies M, Geelhoed E, et al. Secondary preventive medication use in a prevalent population-based cohort of acute coronary syndrome survivors. Cardiovasc Ther. 2016;34(6):423-30. https://doi.org/10.1111/1755-5922.12212 PMid:27489053 DOI: https://doi.org/10.1111/1755-5922.12212

Khedri M, Szummer K, Carrero JJ, Jernberg T, Evans M, Jacobson SH, et al. Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function. Eur J Prev Cardiol. 2017;24(7):724-34. https://doi.org/10.1177/2047487317693950 PMid:28195517 DOI: https://doi.org/10.1177/2047487317693950

Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm. 2008;14(3):271-80. https://doi.org/10.18553/jmcp.2008.14.3.271 PMid:18439049 DOI: https://doi.org/10.18553/jmcp.2008.14.3.271

Kim MJ, Jeon DS, Gwon HC, Kim SJ, Chang K, Kim HS, et al. Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: Multicenter survey in Korea. Clin Cardiol. 2012;35(11):700-6. https://doi.org/10.1002/clc.22038 PMid:22825844 DOI: https://doi.org/10.1002/clc.22038

Zeymer U, Berkenboom G, Coufal Z, Belger M, Sartral M, Norrbacka K, et al. Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: Results from the antiplatelet treatment observational registries (APTOR). Int J Cardiol. 2013;170(2):239-45. https://doi.org/10.1016/j.ijcard.2013.10.057 PMid:24225199 DOI: https://doi.org/10.1016/j.ijcard.2013.10.057

Ferreira-González I, Carrillo X, Martín V, de la Torre Hernández JM, Baz JA, Navarro Manchón J, et al. Interhospital variability in drug prescription after acute coronary syndrome: Insights from the ACDC study. Rev Esp Cardiol (Engl Ed). 2016;69(2):117-24. https://doi.org/10.1016/j.rec.2015.04.018 PMid:26253861 DOI: https://doi.org/10.1016/j.rec.2015.04.018

Mantel Ä, Holmqvist M, Jernberg T, Wållberg-Jonsson S, Askling J. Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(12):2017-24. https://doi.org/10.1136/annrheumdis-2017-211608 PMid:28823986 DOI: https://doi.org/10.1136/annrheumdis-2017-211608

Turner RM, Yin P, Hanson A, FitzGerald R, Morris AP, Stables RH, et al. Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. J Clin Lipidol. 2017;11(1):204-14. https://doi.org/10.1016/j.jacl.2016.12.007 PMid:28391887 DOI: https://doi.org/10.1016/j.jacl.2016.12.007

Al-Zakwani I, Zubaid M, Alsheikh-Ali AA, Almahmeed W, Rashed W. Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry. Cardiovasc Ther. 2018;36(6):e12463. https://doi.org/10.1111/1755-5922.12463 PMid:30079461 DOI: https://doi.org/10.1111/1755-5922.12463

Sun Y, Xie G, Patel A, Li S, Zhao W, Yang X, et al. Prescription of statins at discharge and 1-year risk of major clinical outcomes among acute coronary syndromes patients with extremely low LDL-cholesterol in clinical pathways for acute coronary syndromes studies. Clin Cardiol. 2018;41(9):1192-200. https://doi.org/10.1002/clc.23040 PMid:30084224 DOI: https://doi.org/10.1002/clc.23040

Gencer B, Auer R, Nanchen D, Räber L, Klingenberg R, Carballo D, et al. Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis. 2015;239(1):118-24. https://doi.org/10.1016/j.atherosclerosis.2014.12.049 PMid:25585031 DOI: https://doi.org/10.1016/j.atherosclerosis.2014.12.049

Bourdès V, Ferrières J, Amar J, Amelineau E, Bonnevay S, Berlion M, et al. Prediction of persistence of combined evidence-based cardiovascular medications in patients with acute coronary syndrome after hospital discharge using neural networks. Med Biol Eng Comput. 2011;49(8):947-55. https://doi.org/10.1007/s11517-011-0785-4 PMid:21598000 DOI: https://doi.org/10.1007/s11517-011-0785-4

Wang R, Neuenschwander FC, Lima Filho A, Moreira CM, Santos ES, Reis HJ, et al. Use of evidence-based interventions in acute coronary syndrome - Subanalysis of the ACCEPT registry. Arq Bras Cardiol. 2014;102(4):319-26. https://doi.org/10.5935/abc.20140033 PMid:24652052 DOI: https://doi.org/10.5935/abc.20140033

Desta DM, Nedi T, Hailu A, Atey TM, Tsadik AG, Asgedom SW, et al. Treatment outcome of acute coronary syndrome patients admitted to Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia; A retrospective cross-sectional study. PLoS One. 2020;15(2):e0228953. https://doi.org/10.1371/journal.pone.0228953 PMid:32053702 DOI: https://doi.org/10.1371/journal.pone.0228953

Andrikopoulos G, Tzeis S, Nikas N, Richter D, Pipilis A, Gotsis A, et al. Short-term outcome and attainment of secondary prevention goals in patients with acute coronary syndrome-results from the countrywide TARGET study. Int J Cardiol. 2013;168(2):922-7. https://doi.org/10.1016/j.ijcard.2012.10.049 PMid:23186596 DOI: https://doi.org/10.1016/j.ijcard.2012.10.049

Pereira M, Araújo C, Dias P, Lunet N, Subirana I, Marrugat J, et al. Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: The EURHOBOP study. Eur J Prev Cardiol. 2014;21(11):1401-8. https://doi.org/10.1177/2047487313494580 PMid:23787795 DOI: https://doi.org/10.1177/2047487313494580

Huffman MD, Prabhakaran D, Abraham AK, Krishnan MN, Nambiar AC, Mohanan PP. Optimal in-hospital and discharge medical therapy in acute coronary syndromes in Kerala: Results from the Kerala acute coronary syndrome registry. Circ Cardiovasc Qual Outcomes. 2013;6(4):436-43. https://doi.org/10.1161/circoutcomes.113.000189 PMid:23800985 DOI: https://doi.org/10.1161/CIRCOUTCOMES.113.000189

Ozawa S, Shankar R, Leopold C, Orubu S. Access to medicines through health systems in low- and middle-income countries. Health Policy Plan. 2019;34:iii1-3. https://doi.org/10.1093/heapol/czz119 DOI: https://doi.org/10.1093/heapol/czz119

De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: A systematic review. Br J Clin Pharmacol. 2014;78(4):684-98. https://doi.org/10.1111/bcp.12339 PMid:25364801 DOI: https://doi.org/10.1111/bcp.12339

Simpson RJ Jr., Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic review. J Clin Lipidol. 2010;4(6):462-71. https://doi.org/10.1016/j.jacl.2010.08.026 PMid:21122692 DOI: https://doi.org/10.1016/j.jacl.2010.08.026

Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T. Post-myocardial infarction (MI) care: Medication adherence for secondary prevention after MI in a large real-world population. Clin Ther. 2019;41(1):107-17. https://doi.org/10.1016/j.clinthera.2018.11.012 PMid:30591287 DOI: https://doi.org/10.1016/j.clinthera.2018.11.012

Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: A meta-analysis. Can J Cardiol. 2012;28(5):574-80. https://doi.org/10.1016/j.cjca.2012.05.007 PMid:22884278 DOI: https://doi.org/10.1016/j.cjca.2012.05.007

Mathews R, Wang TY, Honeycutt E, Henry TD, Zettler M, Chang M, et al. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. Am Heart J. 2015;170(1):62-9. https://doi.org/10.1016/j.ahj.2015.03.019 PMid:26093865 DOI: https://doi.org/10.1016/j.ahj.2015.03.019

Gencer B, Rodondi N, Auer R, Räber L, Klingenberg R, Nanchen D, et al. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. Eur J Intern Med. 2015;26(1):56-62. https://doi.org/10.1016/j.ejim.2014.12.014 PMid:25582072 DOI: https://doi.org/10.1016/j.ejim.2014.12.014

Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Am Heart J. 2009;157(1):141-8. https://doi.org/10.1016/j.ahj.2008.08.012 PMid:19081410 DOI: https://doi.org/10.1016/j.ahj.2008.08.012

Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017;3(3):163-82. https://doi.org/10.1093/ehjcvp/pvw042 PMid:28329228 DOI: https://doi.org/10.1093/ehjcvp/pvw042

Yang HY, Huang JH, Hsu CY, Chen YJ. Gender differences and the trend in the acute myocardial infarction: A 10-year nationwide population-based analysis. ScientificWorldJournal. 2012;2012:184075. PMid:22997490 DOI: https://doi.org/10.1100/2012/184075

Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;130(25):2354-94. https://doi.org/10.1161/cir.0000000000000133 PMid:25249586 DOI: https://doi.org/10.1161/CIR.0000000000000133

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-350. https://doi.org/10.1161/cir.0000000000000700 PMid:30423393 DOI: https://doi.org/10.1161/CIR.0000000000000700

Deedwania PC. Statins in chronic kidney disease: Cardiovascular risk and kidney function. Postgrad Med. 2014;126(1):29-36. https://doi.org/10.3810/pgm.2014.01.2722 PMid:24393749 DOI: https://doi.org/10.3810/pgm.2014.01.2722

Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124(2):328-50. PMid:30653440 DOI: https://doi.org/10.1161/CIRCRESAHA.118.312782

Swallow DM, Lawton MA, Grosset KA, Malek N, Klein J, Baig F, et al. Statins are underused in recent-onset Parkinson’s disease with increased vascular risk: Findings from the UK Tracking Parkinson’s and Oxford Parkinson’s Disease Centre (OPDC) discovery cohorts. J Neurol Neurosurg Psychiatry. 2016;87(11):1183-90. https://doi.org/10.1136/jnnp-2016-313642 PMid:27671901 DOI: https://doi.org/10.1136/jnnp-2016-313642

Grey C, Jackson R, Wells S, Thornley S, Marshall R, Crengle S, et al. Maintenance of statin use over 3 years following acute coronary syndromes: A national data linkage study (ANZACS-QI-2). Heart. 2014;100(10):770-4. https://doi.org/10.1136/heartjnl-2013-304960 PMid:24436219 DOI: https://doi.org/10.1136/heartjnl-2013-304960

Zeymer U, James S, Berkenboom G, Mohacsi A, Iniguez A, Coufal Z, et al. Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI. Eur J Prev Cardiol. 2013;20(2):218-28. https://doi.org/10.1177/2047487312437060 PMid:22345684 DOI: https://doi.org/10.1177/2047487312437060